Pharvaris reports Q3 results
Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger sell pressure, but the recent late‑stage trial win could provide upside if investors focus on future growth.
Market read
Micro‑cap biotech earnings with a loss; short‑term downside expected, but trial success offers a longer‑term catalyst.
What to watch
Potential upcoming regulatory approval timeline and cash runway may mitigate short‑term downside.
Background
Pharvaris N.V. (PHVS) released its Q3 2026 earnings, showing a net loss of €47.4M and EPS of -$0.67.
Ticker impact
Q3 results disclosed EPS -$0.67 and net loss €47.4M for Pharvaris N.V.
likely downside as market prices in the loss
The company reported a larger-than-expected loss, which typically triggers sell pressure in biotech microcaps.
Market effects
Biotech sector may see modest pullback as earnings disappointment spreads to peers.
European biotech investors could see slight sentiment dip.
Limited to niche biotech investors; no broad market effect.
Counterpoint
If the Phase III trial data is viewed as a long‑term catalyst, the stock could rebound despite the loss.
Key entities
- companyPharvaris N.V.
Biotech firm developing treatments for hereditary angioedema.

